Sheng Shupei, Jin Limin, Zhang Yan, Sun Weiting, Mei Lin, Zhu Dunwan, Dong Xia, Lv Feng
Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, PR China.
ACS Nano. 2024 Feb 13;18(6):4981-4992. doi: 10.1021/acsnano.3c10862. Epub 2024 Jan 9.
During wound healing after cancer surgery, platelets, neutrophils, and macrophages accumulate at the wound site and induce important pathophysiological features. Utilizing these pathophysiological features, the development of targeted delivery systems for postoperative tumor immunotherapy is an important strategy. Herein, a twindrive precise delivery system of hybrid membrane combined with CD47 blocking is developed for targeted delivery and targeted regulation to induce postoperative immunotherapy. The precise delivery system consists of IR820-modified platelet-neutrophil hybrid membranes loaded with R848 nanoparticles. Based on the pathological characteristics of platelet aggregation and neutrophil tendency caused by the wound inflammatory microenvironment after tumor surgery, the twindrive delivery system could achieve targeted delivery and targeted regulation of immune drugs to tumor sites. After precise delivery guided by fluorescence imaging, R848 is targeted to reprogram M2 macrophages into M1 macrophages, stimulate dendritic cell maturation as an adjuvant, and then activate T cell immunity. R848 polarization and CD47 blockade together enhanced the phagocytosis function of macrophages, which combined with T cell-mediated cellular immune response to finally effectively inhibit postsurgical tumor recurrence, metastasis, and prolonged survival time. It develops a targeted delivery and regulatory system for cell-specific responses to the pathophysiological features of wound healing for postoperative immunotherapy.
Int J Biol Macromol. 2023-11-1
J Exp Clin Cancer Res. 2024-2-27
Cell Commun Signal. 2024-3-11
J Immunother Cancer. 2022-2
J Immunother Cancer. 2021-3
Cancer Cell Int. 2025-7-11
Burns Trauma. 2025-2-10
Exp Hematol Oncol. 2025-6-13
Acta Pharm Sin B. 2024-12
Bioact Mater. 2024-3-10